The company has various projects and launches scheduled for 2020 as part of its anniversary celebration.
The United States Pharmacopeia (USP), a nonprofit organization that builds trust in medicines, supplements, and foods through public quality standards that help assure quality and safety, announced that January 2020 marks its 200th anniversary.
According to a Jan. 6, 2020 company press release, USP has various projects and launches scheduled for 2020 as part of its anniversary celebration. The events include:
"Billions of people live longer and healthier lives thanks to medicines they can trust," said Ronald T. Piervincenzi, PhD, CEO, USP, in the press release. "Our public quality standards build patient, practitioner, and industry confidence by setting clear quality expectations and increasing patient access to vital therapies. Governments in the US and around the world rely on the thousands of USP standards to make sure quality medicines are available to their populations, and that poor-quality and counterfeit drugs do not enter the market."
"We're working to help ensure that today's remarkable innovations can be tomorrow's trusted therapies, just as we have done for 200 years," Piervincenzi added.
Source: USP
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.